Picosulfuric Acid

Summary

Picosulfuric Acid (CHEMBL1741134) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 13
• Chemistry: 437.4 Da · C18H15NO8S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1741134
Name	Picosulfuric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5243
Molecular formula	C18H15NO8S2
Molecular weight	437.4
InChIKey	UJIDKYTZIQTXPM-UHFFFAOYSA-N

SMILES: C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)O)C3=CC=C(C=C3)OS(=O)(=O)O

IUPAC name: [4-[pyridin-2-yl-(4-sulfooxyphenyl)methyl]phenyl] hydrogen sulfate

Also known as: Picosulfate, Sodium Picosulfate

Parent form; salt/anhydrous children: CHEMBL1697768

Patent coverage: 31 distinct patent families (64 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	5
PHASE4	4
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06580366	PHASE4	NOT_YET_RECRUITING	Comparing Sennosid A+B and Sodium Picosulfate/Magnesium Oxide/Citric Acid for Bowel Preparation
NCT01554111	PHASE4	COMPLETED	Comparing Bowel Preparation Regimens for Flexible Sigmoidoscopy
NCT03581149	PHASE4	UNKNOWN	Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients
NCT04598880	PHASE4	COMPLETED	Comparison of 1 Liter PEG With Ascorbate and Sodium Picosulfate / Magnesium Citrate for High Quality Colon Cleansing
NCT07218523	PHASE3	RECRUITING	A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
NCT01984008	PHASE3	COMPLETED	A Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy
NCT03074448	PHASE3	COMPLETED	Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation
NCT05144295	PHASE3	COMPLETED	Lubiprostone for Functional Constipation in the Under 18 Years Patients
NCT05726097	PHASE3	COMPLETED	Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
NCT02979223	PHASE2	COMPLETED	Combination Method Using Sodium Picosulfate and Magnesium Citrate and PEG With Ascorbic Acid for Bowel Preparation
NCT02211911	PHASE1	COMPLETED	Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females
NCT04033250	Not specified	UNKNOWN	Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation
NCT04153084	Not specified	UNKNOWN	Study of Different Endoscopic Preparations Used in Pediatric Colonoscopy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).